Inmune Bio, Inc. financial data

Symbol
INMB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
225 Ne Mizner Blvd, Suite 640, Boca Raton, Florida
State of incorporation
Nevada
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 265 % -68.9%
Debt-to-equity 46 % +46.3%
Return On Equity -46.3 %
Return On Assets -58.4 % -77.5%
Operating Margin -26.2K % -152%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18M shares +0.45%
Common Stock, Shares, Outstanding 18M shares +0.03%
Entity Public Float 106M USD +2.91%
Common Stock, Value, Issued 18K USD 0%
Weighted Average Number of Shares Outstanding, Basic 18M shares +0.45%
Weighted Average Number of Shares Outstanding, Diluted 18M shares +0.45%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 131K USD -47.4%
Research and Development Expense 24.8M USD +47%
General and Administrative Expense 9.63M USD +4.1%
Operating Income (Loss) -34.3M USD -32.6%
Nonoperating Income (Expense) -1.6M USD -1720%
Net Income (Loss) Attributable to Parent -34.5M USD -28.1%
Earnings Per Share, Basic -1.92 USD/shares -28.9%
Earnings Per Share, Diluted -1.92 USD/shares -28.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26M USD -49%
Assets, Current 29.8M USD -47.6%
Operating Lease, Right-of-Use Asset 389K USD -19.8%
Intangible Assets, Net (Excluding Goodwill) 16.5M USD 0%
Other Assets, Noncurrent 106K USD +7.07%
Assets 46.8M USD -36.7%
Liabilities, Current 17.5M USD +69.7%
Operating Lease, Liability, Noncurrent 360K USD -27.7%
Liabilities 17.8M USD -4.67%
Accumulated Other Comprehensive Income (Loss), Net of Tax -669K USD +5.51%
Retained Earnings (Accumulated Deficit) -132M USD -35.4%
Stockholders' Equity Attributable to Parent 28.2M USD -49%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 50.7M USD -27.6%
Liabilities and Equity 46.8M USD -36.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.48M USD -555%
Net Cash Provided by (Used in) Financing Activities -2.5M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 18M shares +0.03%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.85M USD -756%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26M USD -49%
Interest Paid, Excluding Capitalized Interest, Operating Activities 302K USD -32.9%
Deferred Tax Assets, Valuation Allowance 19.6M USD +42.8%
Deferred Tax Assets, Gross 19.6M USD +43.1%
Operating Lease, Liability 485K USD -19.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.5M USD -24.4%
Lessee, Operating Lease, Liability, to be Paid 581K USD
Operating Lease, Liability, Current 125K USD +17.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 198K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 192K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 96K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 51K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.85M USD +25.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 51K USD
Additional Paid in Capital 161M USD +4.81%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 7.37M USD +3.06%
Interest Expense 357K USD -41.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%